Reversal of Acute Clinical and Experimental Organ Rejection Using Large Doses of Intravenous Prednisolone

Bell, P. R. F.; Calman, K.C.; Wood, R. F.; Briggs, J. D.; Paton, Alex; Macpherson, Stuart; Kyle, K. F.

doi:10.1016/s0140-6736(71)92441-x

Cited by 108 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However the presence of side effects restricted their usage. To reduce these side effects, pulse corticosteroid therapy was introduced in autoimmune disorders (5,6). In 1975, Burton and Shuster first performed this treatment modality in AA.…”

Section: Discussionmentioning

confidence: 99%

Pulse methylprednisolone therapy for the treatment of extensive alopecia areata

Açıkgöz

Özmen²,

Çayirli³

et al. 2013

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Pulse methylprednisolone therapy for the treatment of extensive alopecia areata

Açıkgöz

Özmen²,

Çayirli³

et al. 2013

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…Intravenous méthylprednisolone has been used in the treatment of allograft rejection [6], rapidly progressing nephritis [7], mixed cryoglobulinemia nephropathy [8], minimal-change nephrotic syndrome [9], and the glomer ulonephritis of systemic lupus erythematosus [10]. Rose et al [11] reported the use of méthylprednisolone therapy in 2 patients with FSGS and nephrotic syndrome.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Childhood Prednisone-Resistant Nephrotic Syndrome and Focal Segmental Glomerulosclerosis with Intravenous Methylprednisolone and Oral Alkylating Agents

Griswold¹,

Tune²,

Reznik³

et al. 1987

Nephron

View full text Add to dashboard Cite

Patients with prednisone-resistant nephrotic syndrome and biopsy-proven focal segmental glomerulosclerosis were treated with intravenous methylprednisone. After the first 2 weeks of therapy, the average urine protein excretion decreased from 247 to 96 mg/m²/h (p < 0.04). Two of the 7 patients have had long-term, nearly complete remissions. The other patients relapsed. One relapsing patient was retreated with methylprednisolone and is now in remission. Four relapsing patients were treated with alkylating agents, in combination with methylprednisolone. All of these patients entered complete or partial remissions. Methylprednisolone causes a significant decrease in the proteinuria of children with focal segmental glomerulosclerosis. In addition, although the follow-up period is relatively short, it would appear that methylprednisolone, often in conjunction with an alkylating agent, has significantly improved the clinical status of these patients.

show abstract

“…Drug reactions, autoimmune hemolytic anemia, hypergammaglobulinemia, cuta neous anergy, cytological and histological features of AIL indicate a serious immuno logical disorder attributed to hyperfunction of the B lymphocyte system following a loss of suppressor T cells [1], Knowing that in travenous pulse méthylprednisolone therapy has been successfully used in the treatment of other disorders associated with severe im mune alteration such as lupus nephritis [3], renal graft rejection [4] and rhumatoid ar thritis [5], we decided to try this treatment in our patient as a last resort after CHOP failure. The complete remission obtained as well as the possibility of retreatment follow ing a relapse led us to think that methylprednisolone as pulse therapy could be an appropriate treatment of severe AIL.…”

Section: Discussionmentioning

confidence: 99%